In Part 4 of this 5-part series, our roundtable takes on the topics of marketing and outreach to physicians, changing attitudes about hearing aids in younger patients, and a greater willingness to try new technology.
Researchers supported by the National Institutes of Health (NIH) are launching a clinical trial to test a device that uses nervous system stimuli to rewire parts of the brain, in hopes of significantly reducing or removing tinnitus.
Research reveals why hearing loss is correlated with auditory signals failing to get transmitted along the auditory nerve.
The first patient has been enrolled in a study designed to evaluate the efficacy, safety, and tolerability of intratympanic injections of AM-101 in the treatment of acute peripheral tinnitus following traumatic cochlear injury or otitis media.
Neuromonics is introducing what it calls an easy-to-use device to help tinnitus sufferers manage symptoms on demand. The Haven serves as a step between Neuromonics’ Oasis™ and Sanctuary™ devices.
The chirps of field crickets are a common part of the nocturnal sounds in summer and fall in Southern California.
An important finding was that study animals that did not get tinnitus showed fewer changes in their multisensory plasticity than those with tinnitus. In other words, their neurons were not hyperactive.
Researchers at the University of Colorado School of Medicine may have figured out what causes Meniere’s disease and how to attack it.
UT-Dallas researchers demonstrated that treating tinnitus using vagus nerve stimulation-tone (VNS) therapy brought significant improvement to some of the participants in a small clinical trial.
Neuromonics Inc, Westminster, Colo, manufacturer and distributor of tinnitus treatment devices, has named Eula Adams its new CEO.